cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.8230529.v1
title: Supplementary Material for: Lobar Quantification by Ventilation/Perfusion SPECT/CT in Patients with Severe Emphysema Undergoing Lung Volume Reduction with Endobronchial Valves

description: <b><i>Background:</i></b> Endoscopic lung volume reduction (ELVR) therapy using one-way valves is used to treat chronic obstructive pulmonary disease patients with severe heterogeneous emphysema. A successful treatment results in atelectasis of the treated pulmonary lobe with subsequent reduction of ventilation (V) and perfusion (Q). <b><i>Objective:</i></b> We evaluated the effects of ELVR on the targeted lobe using a new 3-dimensional ventilation and perfusion (V/Q) single-photon emission computed tomography (SPECT)/computed tomography (CT) analysis, which allows for simultaneous semi-automatic lobar pulmonary quantification of volume, ventilation and perfusion, on the first consecutive patients treated with ELVR at Rigshospitalet, Denmark. V/Q planar scintigraphy and V/Q SPECT/CT and lung function measurements were performed before and 6 months after intervention. <b><i>Results:</i></b> We included 24 subjects (60 years, range 46–74 years; 37.5% men) with a baseline FEV<sub>1</sub> of 25% predicted and RV of 257% predicted. V/Q SPECT/CT-assessed volume of the targeted lobe decreased by a mean of –395 mL and a relative mean of –26.8%, whilst ventilation and perfusion decreased by a relative mean of –37.1 and –25.7%. There was a significant increase in the same parameters of the non-targeted lobe(s) on the ipsilateral side. None of these changes were found in the analysis of planar V/Q imaging. The total lung volume decreased on average by –420 mL. Six months after ELVR, FEV<sub>1</sub> had increased by 22%. Significant correlations were found between changes in FEV<sub>1</sub> and changes in the volume of the treated lobe (SPECT/CT). <b><i>Conclusion:</i></b> Semi-automatic SPECT/CT analysis can quantify volume, ventilation and perfusion changes in pulmonary lobes and may be used in the assessment of patient eligibility for ELVR, identifying target lobes, and evaluation of the regional effects of treatment.
DOI: 10.6084/m9.figshare.8230514
title: Supplementary Material for: Rapid and Efficient Differentiation of Rodent Neural Stem Cells into Oligodendrocyte Progenitor Cells

description: Oligodendrocyte progenitor cells (OPCs) may have beneficial effects in cell replacement therapy of neurodegenerative disease owing to their unique capability to differentiate into myelinogenic oligodendrocytes (OLs) in response to extrinsic signals. Therefore, it is of significance to establish an effective differentiation methodology to generate highly pure OPCs and OLs from some easily accessible stem cell sources. To achieve this goal, in this study, we present a rapid and efficient protocol for oligodendroglial lineage differentiation from mouse neural stem cells (NSCs), rat NSCs, or mouse embryonic stem cell-derived neuroepithelial stem cells. In a defined culture medium containing Smoothened Agonist, basic fibroblast growth factor, and platelet-derived growth factor-AA, OPCs could be generated from the above stem cells over a time course of 4–6 days, achieving a cell purity as high as ∼90%. In particular, these derived OPCs showed high expandability and could further differentiate into myelin basic protein-positive OLs within 3 days or alternatively into glial fibrillary acidic protein-positive astrocytes within 7 days. Furthermore, transplantation of rodent NSC-derived OPCs into injured spinal cord indicated that it is a feasible strategy to treat spinal cord injury. Our results suggest a differentiation strategy for robust production of OPCs and OLs from rodent stem cells, which could provide an abundant OPC source for spinal cord injury.
DOI: 10.6084/m9.figshare.8230520.v1
title: Supplementary Material for: Low Platelet Counts at Diagnosis Predict Better Survival for Patients with Intermediate-Risk Acute Myeloid Leukemia

description: <b><i>Background:</i></b> Aggressive growth of primitive and immature cells in the bone marrow results in reductions in megakaryocyte and platelet (PLT) counts, leading to thrombocytopenia in acute myeloid leukemia (AML). However, not all AML patients show thrombocytopenia at the time of diagnosis, and the association of PLT count with patient survival is largely unknown. <b><i>Methods:</i></b> A retrospective study was performed to determine PLT counts at diagnosis in the peripheral blood in 291 newly diagnosed AML patients and assess the association of PLT counts with the overall survival (OS) and disease-free survival (DFS) of these patients. <b><i>Results:</i></b> Low PLT counts (≤40 × 10<sup>9</sup>/L) were associated with better outcomes for the whole cohort (5-year OS, 55.1 ± 3.8 vs. 35.3 ± 3.5%, <i>p</i> &lt; 0.001; 5-year DFS, 49.1 ± 3.8 vs. 25.7 ± 4.0%, <i>p</i> &lt; 0.001) and intermediate-risk patients (5-year OS, 64.5 ± 5.4 vs. 41.0 ± 4.8%, <i>p</i> &lt; 0.001; 5-year DFS, 60.8 ± 5.6 vs. 28.6 ± 5.6%, <i>p</i> &lt; 0.001). Moreover, low PLT counts were related to deeper molecular remission. Low PLT counts correlated with better survival of intermediate-risk AML patients treated with chemotherapy only. Allogeneic hematopoietic stem cell transplantation attenuated the negative impact of high PLT counts on the survival of intermediate-risk patients. Furthermore, univariate and multivariate analyses demonstrated that PLT count at diagnosis was an independent prognostic factor for intermediate-risk AML. <b><i>Conclusion:</i></b> PLT count at diagnosis predicts survival for patients with intermediate-risk AML.
DOI: 10.6084/m9.figshare.8230505
title: female_evm.gff3

description: Turbot (<i>Scophthalmus maximus</i>) is a commercially important species and is among the most produced flatfish in aquaculture. It has a drastic sexual dimorphism where females are larger. We sequenced and de novo assembled female and male genomes in the present study.
DOI: 10.6084/m9.figshare.8230487
title: Supplementary Material for: Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies

description: The prevalence of safety-related postmarketing label modifications of medications for hematological malignancies is unknown. We identified 35 new drugs indicated for hematological malignancies approved by the US Food and Drug Administration between January 1999 and December 2014. Characteristics of supporting trials and safety-related label modifications from approval to December 2017 were collected from drug labels. Regulatory review and approval pathways were also collected. New drug approvals were supported by trials with a median of 167 patients (interquartile range 115–316). All drugs were approved based on surrogate endpoints. Twenty-seven drug approvals (77%) were not supported by randomized controlled trials. All drugs received orphan drug designation, and most were granted fast track designation, priority review, and accelerated approval (83, 74, and 60%, respectively). A total of 28 drugs (80%) had postmarketing safety-related label modifications. Additions to black box warnings, contraindications, warnings and precautions, and common adverse reactions were identified in 31, 11, 77, and 46% of drugs, respectively. Five drugs (14%) were permanently or temporarily withdrawn from the US market. Drugs for hematological malignancies are often approved based on limited evidence through expedited regulatory pathways with incomplete safety profiles. Hematologists should be vigilant for unrecognized side effects when prescribing newly approved drugs.
DOI: 10.6084/m9.figshare.8230487.v1
title: Supplementary Material for: Safety-Related Postmarketing Modifications of Drugs for Hematological Malignancies

description: The prevalence of safety-related postmarketing label modifications of medications for hematological malignancies is unknown. We identified 35 new drugs indicated for hematological malignancies approved by the US Food and Drug Administration between January 1999 and December 2014. Characteristics of supporting trials and safety-related label modifications from approval to December 2017 were collected from drug labels. Regulatory review and approval pathways were also collected. New drug approvals were supported by trials with a median of 167 patients (interquartile range 115–316). All drugs were approved based on surrogate endpoints. Twenty-seven drug approvals (77%) were not supported by randomized controlled trials. All drugs received orphan drug designation, and most were granted fast track designation, priority review, and accelerated approval (83, 74, and 60%, respectively). A total of 28 drugs (80%) had postmarketing safety-related label modifications. Additions to black box warnings, contraindications, warnings and precautions, and common adverse reactions were identified in 31, 11, 77, and 46% of drugs, respectively. Five drugs (14%) were permanently or temporarily withdrawn from the US market. Drugs for hematological malignancies are often approved based on limited evidence through expedited regulatory pathways with incomplete safety profiles. Hematologists should be vigilant for unrecognized side effects when prescribing newly approved drugs.
DOI: 10.6084/m9.figshare.8230178
title: Results of survey about reusbality in Artificial neural networks

description: The results of our survey on state of reusablity among experts of artificial neural networks<br>
DOI: 10.6084/m9.figshare.8230178.v1
title: Results of survey about reusbality in Artificial neural networks

description: The results of our survey on state of reusablity among experts of artificial neural networks<br>
DOI: 10.6084/m9.figshare.8229851
title: Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment

description: <b>Objective:</b> The conservative treatment of endometrial hyperplasia without atypia (HWA), atypical endometrial hyperplasia (AH/EIN) and early endometrioid carcinoma (EEC) is based on progestins. We aimed to assess whether diabetes mellitus affects the responsiveness of HWA, AH/EIN and EEC to conservative treatment, through a systematic review and meta-analysis. <b>Study design:</b> Electronic databases were searched for studies assessing the outcome of conservative treatment in HWA, AH/EIN and EEC, stratified based on the diagnosis of diabetes mellitus. The association of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A <i>p</i>-value <b>Results:</b> Six studies with 876 patients (383 HWA, 365 AH/EIN and 128 EEC) were included. Overall, diabetes mellitus was not associated with outcome of treatment (OR = 1.20; <i>p</i> = .62). The association was not significant in both the HWA subgroup (OR = 0.95; <i>p</i> = .93) and in AH/EIN and EEC subgroup (OR = 1.43; <i>p</i> = .46). There was no significant risk of publication bias. <b>Conclusions:</b> Diabetes mellitus does not affect the outcome of conservative treatment in HWA, AH/EIN and EEC.
DOI: 10.6084/m9.figshare.8229851.v1
title: Diabetes mellitus and responsiveness of endometrial hyperplasia and early endometrial cancer to conservative treatment

description: <b>Objective:</b> The conservative treatment of endometrial hyperplasia without atypia (HWA), atypical endometrial hyperplasia (AH/EIN) and early endometrioid carcinoma (EEC) is based on progestins. We aimed to assess whether diabetes mellitus affects the responsiveness of HWA, AH/EIN and EEC to conservative treatment, through a systematic review and meta-analysis. <b>Study design:</b> Electronic databases were searched for studies assessing the outcome of conservative treatment in HWA, AH/EIN and EEC, stratified based on the diagnosis of diabetes mellitus. The association of diabetes mellitus with treatment failure was assessed by using odds ratio (OR). A <i>p</i>-value <b>Results:</b> Six studies with 876 patients (383 HWA, 365 AH/EIN and 128 EEC) were included. Overall, diabetes mellitus was not associated with outcome of treatment (OR = 1.20; <i>p</i> = .62). The association was not significant in both the HWA subgroup (OR = 0.95; <i>p</i> = .93) and in AH/EIN and EEC subgroup (OR = 1.43; <i>p</i> = .46). There was no significant risk of publication bias. <b>Conclusions:</b> Diabetes mellitus does not affect the outcome of conservative treatment in HWA, AH/EIN and EEC.
DOI: 10.6084/m9.figshare.8229563
title: Processed Data.xlsx

description: Creep Testing of Thermoeelctric Materials
DOI: 10.6084/m9.figshare.8229287
title: Raw Data.xlsx

description: Creep Testing of Thermoelectric Materials
DOI: 10.6084/m9.figshare.8229563.v1
title: Processed Data.xlsx

description: Creep Testing of Thermoeelctric Materials
DOI: 10.6084/m9.figshare.8229287.v1
title: Raw Data.xlsx

description: Creep Testing of Thermoelectric Materials
DOI: 10.6084/m9.figshare.8229236
title: FT4curves_different_dose.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4curves_different_dose.m is used to plot the predicted FT4 curves for different drug dosages as shown in Figure 1.
DOI: 10.6084/m9.figshare.8229239
title: Copy of patient data.xlsx from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: Thyroid over-activity or hyperthyroidism constitutes a significant morbidity afflicting the world. The current medical practice of dose titration of anti-thyroid drug (ATD) treatment for hyperthyroidism is relatively archaic, being based on arbitrary and time-consuming trending of thyroid function that requires multiple clinic monitoring visits before an optimal dose is found. This prompts a re-examination into more deterministic and efficient treatment approaches in the present personalized medicine era. Our research project seeks to develop a personalized medicine model that facilitates optimal drug dosing via the titration regimen. We analysed 49 patients' data consisting of drug dosage, time period and serum free thyroxine (FT4). Ordinary differential equation modelling was applied to describe the dynamic behaviour of FT4 concentration. With each patient's data, an optimization model was developed to determine parameters of synthesis rate, decay rate and IC<sub>50</sub>. We derived the closed-form time- and dose-dependent solution which allowed explicit estimates of personalized predicted FT4. Our equation system involving time, drug dosage and FT4 can be solved for any variable provided the values of the other two are known. Compared against actual FT4 data within a tolerance, we demonstrated the feasibility of predicting the FT4 subsequent to any prescribed dose of ATD with favourable accuracy using the initial three to five patient-visits' data respectively. This proposed mathematical model may assist clinicians in rapid determination of optimal ATD doses within allowable prescription limits to achieve any desired FT4 within a specified treatment period to accelerate the attainment of euthyroid targets.
DOI: 10.6084/m9.figshare.8229239.v1
title: Copy of patient data.xlsx from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: Thyroid over-activity or hyperthyroidism constitutes a significant morbidity afflicting the world. The current medical practice of dose titration of anti-thyroid drug (ATD) treatment for hyperthyroidism is relatively archaic, being based on arbitrary and time-consuming trending of thyroid function that requires multiple clinic monitoring visits before an optimal dose is found. This prompts a re-examination into more deterministic and efficient treatment approaches in the present personalized medicine era. Our research project seeks to develop a personalized medicine model that facilitates optimal drug dosing via the titration regimen. We analysed 49 patients' data consisting of drug dosage, time period and serum free thyroxine (FT4). Ordinary differential equation modelling was applied to describe the dynamic behaviour of FT4 concentration. With each patient's data, an optimization model was developed to determine parameters of synthesis rate, decay rate and IC<sub>50</sub>. We derived the closed-form time- and dose-dependent solution which allowed explicit estimates of personalized predicted FT4. Our equation system involving time, drug dosage and FT4 can be solved for any variable provided the values of the other two are known. Compared against actual FT4 data within a tolerance, we demonstrated the feasibility of predicting the FT4 subsequent to any prescribed dose of ATD with favourable accuracy using the initial three to five patient-visits' data respectively. This proposed mathematical model may assist clinicians in rapid determination of optimal ATD doses within allowable prescription limits to achieve any desired FT4 within a specified treatment period to accelerate the attainment of euthyroid targets.
DOI: 10.6084/m9.figshare.8229230
title: constraint.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: constraint.m is used to solve the developed optimization model (2.5) to derive the values of the parameters under consideration.
DOI: 10.6084/m9.figshare.8229224
title: FT4andDose_calculation.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4andDose_calculation.m is used to calculate FT4 value and the optimal drug dosage, as shown in Table 4, Table 5, and Table 6.
DOI: 10.6084/m9.figshare.8229236.v1
title: FT4curves_different_dose.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4curves_different_dose.m is used to plot the predicted FT4 curves for different drug dosages as shown in Figure 1.
DOI: 10.6084/m9.figshare.8229221
title: main.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: main.m is used to solve the developed optimization model (2.5) to derive the values of the parameters under consideration.
DOI: 10.6084/m9.figshare.8229227
title: FT4cures_different_dataset.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4cures_different_dataset.m is used to plot the predicted FT4 curves derived with three different data sets as shown in Figure 2.
DOI: 10.6084/m9.figshare.8229230.v1
title: constraint.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: constraint.m is used to solve the developed optimization model (2.5) to derive the values of the parameters under consideration.
DOI: 10.6084/m9.figshare.8229224.v1
title: FT4andDose_calculation.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4andDose_calculation.m is used to calculate FT4 value and the optimal drug dosage, as shown in Table 4, Table 5, and Table 6.
DOI: 10.6084/m9.figshare.8229227.v1
title: FT4cures_different_dataset.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4cures_different_dataset.m is used to plot the predicted FT4 curves derived with three different data sets as shown in Figure 2.
DOI: 10.6084/m9.figshare.8229215
title: FT4_3Dsurface.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4_3Dsurface.m is used to plot a 3D surface in terms of time, drug dosage and FT4, as shown in Figure 3.
DOI: 10.6084/m9.figshare.8229218
title: objfun.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: objfun.m is used to solve the developed optimization model (2.5) to derive the values of the parameters under consideration.
DOI: 10.6084/m9.figshare.8229221.v1
title: main.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: main.m is used to solve the developed optimization model (2.5) to derive the values of the parameters under consideration.
DOI: 10.6084/m9.figshare.8229206
title: Plasma Klotho concentrations predict functional outcome at three months after acute ischemic stroke patients

description: <b>Background:</b> The Klotho protects the cardiovascular system by protecting against cell apoptosis, inhibiting the production of reactive oxygen species, and modulating inflammation. We aimed to investigate relationship of plasma Klotho concentrations with functional outcome at 3 months after acute cerebral infarction. <b>Methods:</b> We prospectively enrolled 262 first-ever acute cerebral infarction patients from whom a blood sample was acquired within 24 h of admission. An enzyme-linked immunosorbent assay was used for evaluating plasma Klotho concentration. Functional outcome on admission and three months was evaluated. <b>Results:</b> Of the 262 patients, 152 (58.0%) were men. The mean age of these patients was 64.7 years. The mean ± standard deviation of plasma Klotho concentrations was 312.7 ± 153.3 pg/mL. As opposed to patients with good outcome, plasma Klotho levels were lower in the poor outcome group (207.8 ± 96.2 <i>vs.</i> 342.5 ± 153.5 pg/mL, <i>p</i> = .001). In multivariate analysis, increased plasma Klotho concentrations were independently associated with good functional outcome (Odds ratio: 2.42, 95% confidence interval: 1.45–4.04, <i>p</i> <b>Conclusions:</b> Increased plasma Klotho concentrations were associated with good functional outcome in patients with acute ischemic stroke. We attribute these associations to the pleiotropic effects of Klotho in stroke and vascular diseases.Key messageIncreased plasma Klotho concentrations were associated with good functional outcome in patients with acute ischemic stroke. Increased plasma Klotho concentrations were associated with good functional outcome in patients with acute ischemic stroke.
DOI: 10.6084/m9.figshare.8229215.v1
title: FT4_3Dsurface.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: FT4_3Dsurface.m is used to plot a 3D surface in terms of time, drug dosage and FT4, as shown in Figure 3.
DOI: 10.6084/m9.figshare.8229218.v1
title: objfun.m from Hyperthyroidism in the personalized medicine era: the rise of mathematical optimization

description: objfun.m is used to solve the developed optimization model (2.5) to derive the values of the parameters under consideration.